Safety and Effectiveness of Inhaling Different Dosage Recombinant Human Interferon α1B for Bronchiolitis in Children: a Systematic Review and Meta-Analysis

Table 1

Basic information of included RCTs.

Study ID	Age (months)	Course of disease (days)	Number		Interventions				Outcome
			High dosage group	Low dosage group	High dosage group	Combination with other drugs	Low dosage group	Combination with other drugs
Huang 2015 [12]	T: 9.23 ± 0.53 C: 9.45 ± 0.62	T: 6.08 ± 1.24 C: 6.10 ± 1.28	80	80	IFNα1b 4 μg/kg qid, 5–7d	Albuterol + budesonide	IFNα1b 2 μg/kg, qid, 5–7d	Albuterol + budesonide	①③⑦
Shang 2014 [10]	—	—	110	110	IFNα1b 4 μg/kg, qid, 5–7d	Albuterol + budesonide	IFNα1b 2 μg/kg, qid, 5–7d	Albuterol + budesonide	②③⑤⑦
Li 2019 [11]	T: 11.83 ± 2.53; C: 11.63 ± 2.17	T: 0.90 ± 0.34; C: 0.92 ± 0.35	30	30	IFNα1b 4 μg/kg, qid, 5–7d	Albuterol + budesonide	IFNα1b 2 μg/kg, qid, 5–7d	Albuterol + budesonide	①②③④⑤⑦
Cai 2020 [14]	6.54 ± 3.10	—	53	53	IFNα1b 4 μg/kg, qid, 5–7d	Albuterol + budesonide	IFNα1b 2 μg/kg, qid,5–7d	Albuterol + budesonide	①②④⑦
Hu 2014 [22]	—	—	17	20	IFNα1b 4 μg/kg, qid, 5–7d	Albuterol + budesonide	IFNα1b 2 μg/kg, qid,5–7d	Albuterol + budesonide	③⑥⑦
Dai 2019 [16]	T: 13.52 ± 3.87; C: 13.63 ± 3.84	T: (5.36 ± 0.74); C: (5.11 ± 0.77)	50	50	IFNα1b 4 μg/kg, qid, 7d	Albuterol + budesonide	IFNα1b 2 μg/kg, qid,7d	Albuterol + budesonide	⑦
Wang 2018 [13]	T: 10.42 ± 0.56; C: 10.31 ± 0.77	T: (2.46 ± 0.68); C: (2.29 ± 0.77)	41	41	IFNα1b 4 μg/kg, qid, 5–7d	—	IFNα1b 2 μg/kg, qid, 5–7d	—	①⑦
Liao 2017 [20]	T: 9.4 ± 0.5; C: 9.6 ± 0.6	—	47	54	IFNα1b 4 μg/kg, qid	Budesonide + ipratropium bromide	IFNα1b 2 μg/kg, qid	Budesonide + ipratropium bromide	②③⑤⑦
Zhao 2018 [17]	T1: 6.69 ± 0.6; T2: 7.44 ± 0.96; C: 7.2 ± 0.84	—	20	40	IFNα1b 4 μg/kg, qid, 5–7d	Albuterol + budesonide	IFNα1b 2 μg/kg, qid, 5–7d	Albuterol + budesonide	④⑦
Xu 2017 [19]	T: 12.21 ± 3.32; C: 13.23 ± 3.45	T: 2.57 ± 0.42; C: 2.51 ± 0.52	40	40	IFNα1b 4 μg/kg, qid, 7d	Budesonide + ambroxol	IFNα1b 2 μg/kg, qid, 7d	Budesonide + ambroxol	①③⑥⑦
Liu 2018 [15]	T: 17.16 ± 6.12; C: 18 ± 2.76	T: 2.57 ± 0.42; C: 2.51 ± 0.52	31	31	IFNα1b 4 μg/kg, qid, 7d	Budesonide + ambroxol	IFNα1b 2 μg/kg, qid, 7d	Budesonide + ambroxol	①③⑥⑦
Chao 2016 [21]	—	1–7	37	40 (tid 20; qid 20)	IFNα1b 4 μg/kg, qid, 5–7d	Budesonide + terbutaline + normal saline	IFNα1b 2 μg/kg, qid, 5–7d	Budesonide + terbutaline + normal saline	①③④⑦
Chen 2018 [18]	T (early):6.0 ± 1.8; C (early):5.5 ± 2.1; T (late):6.9 ± 3.6; C (late):6.8 ± 2.9	—	54 (early 27; late 27)	52 (early 26; late 26)	IFNα1b 4 μg/kg, qid, 5–7d	Budesonide + terbutaline	IFNα1b 2 μg/kg, qid, 5–7d	Budesonide + terbutaline	①⑦

①Qid: twice a day; tid: three times a day; ①the duration of hospital stays; ② three depression sign disappearing times; ③ cough disappearance time; ④ pulmonary rales disappearing time; ⑤ wheeze disappearing time; ⑥ wheezing sound disappearing time; ⑦ adverse event rates. T: high dosage group; C: low dosage group.